Staphylococcus aureus adhesion inhibition

Staphylococcus aureus adhesion inhibition refers to the disruption of the bacterium’s ability to attach to host tissues, extracellular matrix proteins, or medical device surfaces, a critical early step in infection and colonization. This can be achieved by directly targeting surface adhesins (such as ClfA and ClfB, which bind fibrinogen and loricrin, respectively), by inhibiting the regulatory pathways that control adhesin expression (notably the ArlRS–MgrA two-component system, which represses giant surface proteins that shield adhesins), or by blocking the enzyme sortase A (SrtA), which anchors adhesins to the cell wall. Inhibitors like aurintricarboxylic acid, allantodapsone, and Telmisartan have shown promise in reducing adhesion in vitro and in animal models, though none yet eliminate colonization as effectively as traditional antibiotics. These agents represent a novel anti-virulence strategy aimed at preventing S. aureus infections by specifically targeting adhesion mechanisms, with the potential advantage of exerting less selective pressure for resistance development compared to conventional antibiotics[1][2][4].

Other names

S. aureus adhesion inhibitorAnti-adhesion agent against Staphylococcus aureusMicrobial adhesion inhibitorColonization inhibitor

Direct inhibition of adhesin-ligand interaction (e.g., ClfA–fibrinogen, ClfB–loricrin, ClfB–cytokeratin 10); Modulation of surface adhesin display via inhibition of regulatory cascades (ArlRS–MgrA, leading to overexpression of giant inhibitory surface proteins); Inhibition of sortase A (SrtA), blocking the anchoring of adhesins to the cell wall; Force-sensitive catch-bond mechanism under mechanical stress (ClfA).